A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease

This study is testing an investigational drug called DNL628 in people with early-stage Alzheimer's disease. Researchers are evaluating how safe the drug is, how the body processes it, and how it interacts with the biological markers of Alzheimer's disease in the brain. **You may be eligible if...** - You have a diagnosis of probable Alzheimer's disease based on recognized criteria - Your Alzheimer's is at an early stage — mild cognitive impairment or early dementia (Clinical Dementia Rating global score of 0.5 or 1, and MMSE score of 20–30) - You have evidence of Alzheimer's amyloid pathology from historical records or screening tests - Your BMI is between 18 and 32 and you weigh at least 45 kg **You may NOT be eligible if...** - You have another neurological or cognitive condition besides Alzheimer's - You have significant psychiatric conditions - You have unstable or poorly controlled medical conditions (heart, lung, liver, kidney, or hormonal) - You have had another cancer within the past 5 years (with some exceptions for low-risk cancers) Talk to your doctor to see if this trial is right for you.